Kevin Michael Krause - Mar 15, 2024 Form 4/A Insider Report for AN2 Therapeutics, Inc. (ANTX)

Role
Chief Strategy Officer
Signature
/s/ Lucy Day, Attorney-in-Fact for Kevin Michael Krause
Stock symbol
ANTX
Transactions as of
Mar 15, 2024
Transactions value $
$0
Form type
4/A
Date filed
3/29/2024, 04:17 PM
Date Of Original Report
Mar 18, 2024
Previous filing
Jan 11, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ANTX Common Stock Award $0 +30K +1567.4% $0.00 31.9K Mar 15, 2024 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Previously reported on a Form 4 filed on March 18, 2024. As amended, the vesting schedule for the restricted stock units is as follows: 1/4th of the shares vests annually over four years from January 1, 2024, subject to the Reporting Person's continuous service as of such date.